Journal of International Oncology ›› 2020, Vol. 47 ›› Issue (1): 10-17.doi: 10.3760/cma.j.issn.1673-422X.2020.01.002
• Original Articles • Previous Articles Next Articles
Sun Liyun, Lu Yue, Zhang Shunkang, Chen Gang()
Received:
2019-11-26
Revised:
2019-12-10
Online:
2020-01-08
Published:
2020-03-22
Contact:
Chen Gang
E-mail:fodeng73@163.com
Supported by:
Sun Liyun, Lu Yue, Zhang Shunkang, Chen Gang. Survival analysis of postmastectomy radiotherapy for breast cancer staged in cT1-2N1M0 after neoadjuvant chemotherapy with 0-3 metastatic lymph nodes[J]. Journal of International Oncology, 2020, 47(1): 10-17.
"
临床特征 | 放疗组 (n=87) | 未放疗组 (n=41) | χ2值 | P值 | ||||
---|---|---|---|---|---|---|---|---|
年龄(岁) | ||||||||
≤40 | 20 | 9 | 0.017 | 0.896 | ||||
>40 | 67 | 32 | ||||||
月经状态 | ||||||||
绝经前 | 46 | 19 | 0.476 | 0.490 | ||||
绝经后 | 41 | 22 | ||||||
临床分期 | ||||||||
T1N1M0 | 33 | 24 | 4.790 | 0.029 | ||||
T2N1M0 | 54 | 17 | ||||||
pCR | ||||||||
是 | 15 | 10 | 0.906 | 0.341 | ||||
否 | 72 | 31 | ||||||
病理T分期 | ||||||||
T0-Tis | 16 | 10 | ||||||
T1-2 | 69 | 31 | 1.154 | 0.536 | ||||
T3 | 2 | 0 | ||||||
病理分级 | ||||||||
1-2级 | 51 | 22 | ||||||
3级 | 33 | 19 | 1.545 | 0.524 | ||||
不详 | 3 | 0 | ||||||
术后病理N分期 | ||||||||
ypN0 | 44 | 30 | 5.834 | 0.016 | ||||
ypN1 | 43 | 11 | ||||||
病理类型 | ||||||||
浸润性导管癌 | 80 | 40 | 0.691 | 0.406 | ||||
其他 | 7 | 1 | ||||||
脉管瘤栓 | ||||||||
有 | 59 | 25 | 0.578 | 0.447 | ||||
无 | 28 | 16 | ||||||
激素受体状态 | ||||||||
阴性 | 49 | 24 | 0.056 | 0.813 | ||||
阳性 | 38 | 17 | ||||||
HER-2状态 | ||||||||
阴性 | 52 | 20 | ||||||
阳性 | 33 | 20 | 1.605 | 0.490 | ||||
不确定 | 2 | 1 | ||||||
临床特征 | 放疗组 (n=87) | 未放疗组 (n=41) | χ2值 | P值 | ||||
辅助化疗 | ||||||||
无 | 19 | 10 | 0.104 | 0.748 | ||||
有 | 68 | 31 | ||||||
总体化疗周期数 | ||||||||
<6 | 23 | 14 | 0.806 | 0.369 | ||||
≥6 | 64 | 27 | ||||||
靶向治疗 | ||||||||
无 | 69 | 34 | 0.232 | 0.630 | ||||
有 | 18 | 7 | ||||||
内分泌治疗 | ||||||||
无 | 52 | 24 | 0.018 | 0.895 | ||||
有 | 35 | 17 |
"
临床病理特征 | 5年LRFS率 | χ2值 | P值 | 5年DFS率 | χ2值 | P值 | 5年OS率 | χ2值 | P值 | ||
---|---|---|---|---|---|---|---|---|---|---|---|
年龄(岁) | |||||||||||
≤40 | 75.9 | 11.709 | 0.001 | 72.4 | 3.066 | 0.080 | 82.8 | 6.093 | 0.014 | ||
>40 | 96.0 | 85.9 | 96.0 | ||||||||
月经状态 | |||||||||||
绝经前 | 87.7 | 2.173 | 0.140 | 83.1 | 0.004 | 0.948 | 92.3 | 0.075 | 0.748 | ||
绝经后 | 95.2 | 82.5 | 93.7 | ||||||||
临床分期 | |||||||||||
T1 | 87.7 | 1.698 | 0.193 | 78.9 | 0.960 | 0.327 | 93.0 | 0.000 | 0.998 | ||
T2 | 94.4 | 85.9 | 93.0 | ||||||||
pCR | |||||||||||
是 | 96.0 | 0.849 | 0.357 | 92.0 | 1.776 | 0.183 | 96.0 | 0.476 | 0.490 | ||
否 | 90.3 | 80.6 | 92.2 | ||||||||
病理T分期 | |||||||||||
T0-Tis | 100 | 96.2 | 100 | ||||||||
T1-2 | 89.0 | 3.330 | 0.189 | 79.0 | 4.468 | 0.107 | 91.0 | 2.664 | 0.264 | ||
T3 | 100 | 100 | 100 | ||||||||
病理分级 | |||||||||||
1~2级 | 91.8 | 84.9 | 93.2 | ||||||||
3级 | 90.4 | 0.349 | 0.840 | 78.8 | 1.254 | 0.534 | 92.3 | 0.258 | 0.879 | ||
不详 | 100 | 100 | 100 | ||||||||
临床病理特征 | 5年LRFS率 | χ2值 | P值 | 5年DFS率 | χ2值 | P值 | 5年OS率 | χ2值 | P值 | ||
术后病理N分期 | |||||||||||
ypN0 | 93.2 | 0.685 | 0.408 | 82.4 | 0.018 | 0.893 | 95.9 | 2.122 | 0.145 | ||
ypN1 | 88.9 | 83.3 | 88.9 | ||||||||
病理类型 | |||||||||||
浸润性导管癌 | 91.7 | 0.207 | 0.649 | 82.5 | 0.082 | 0.775 | 93.3 | 0.469 | 0.494 | ||
其他 | 91.4 | 87.5 | 87.5 | ||||||||
脉管瘤栓 | |||||||||||
有 | 96.4 | 7.608 | 0.006 | 86.9 | 2.761 | 0.097 | 92.9 | 0.001 | 0.976 | ||
无 | 81.8 | 75.0 | 93.2 | ||||||||
激素受体状态 | |||||||||||
阴性 | 90.4 | 0.268 | 0.605 | 79.5 | 1.448 | 0.229 | 89.0 | 3.974 | 0.046 | ||
阳性 | 92.7 | 87.3 | 98.2 | ||||||||
HER-2状态 | |||||||||||
阴性 | 93.1 | 83.3 | 91.7 | ||||||||
阳性 | 88.7 | 1.076 | 0.584 | 81.1 | 0.733 | 0.693 | 94.3 | 0.486 | 0.784 | ||
不确定 | 100 | 100 | 100 | ||||||||
辅助化疗 | |||||||||||
无 | 93.1 | 0.172 | 0.679 | 89.7 | 1.255 | 0.263 | 93.1 | 0.003 | 0.958 | ||
有 | 90.9 | 80.8 | 92.9 | ||||||||
总化疗周期 | |||||||||||
<6 | 94.6 | 0.745 | 0.388 | 91.9 | 3.091 | 0.079 | 97.3 | 1.550 | 0.213 | ||
≥6 | 90.1 | 79.1 | 91.2 | ||||||||
靶向治疗 | |||||||||||
无 | 91.3 | 0.005 | 0.945 | 84.5 | 1.096 | 0.295 | 93.2 | 0.062 | 0.804 | ||
有 | 92.0 | 76.0 | 92.0 | ||||||||
内分泌治疗 | |||||||||||
无 | 88.2 | 2.525 | 0.112 | 77.6 | 3.428 | 0.064 | 89.5 | 3.455 | 0.063 | ||
有 | 96.2 | 90.4 | 98.1 | ||||||||
术后放疗 | |||||||||||
无 | 85.4 | 3.055 | 0.080 | 68.3 | 9.312 | 0.002 | 90.2 | 0.810 | 0.368 | ||
有 | 94.3 | 89.6 | 94.3 |
[1] | NCCN clinical practice guidelines in oncology: Breast Cancer (Version 1.2018)[EB/OL]. (2018-11-01). [2018-12-28] www.nccn.org/patients. |
[2] | Huang L, Chen S, Yang WT , et al. Risk factors of locoregional relapse in locally advanced breast cancer treated with neoadjuvant chemotherapy following mastectomy and radiotherapy[J]. Oncotarget, 2017,8(24):39703-39710. DOI: 10.18632/oncotarget.14407. |
[3] | Klein J, Tran W, Watkins E , et al. Locally advanced breast cancer treated with neoadjuvant chemotherapy and adjuvant radiotherapy: a retrospective cohort analysis[J]. BMC Cancer, 2019,19(1):306. DOI: 10.1186/s12885-019-5499-2. |
[4] | Li XB, Krishnamurti U, Bhattarai S , et al. Biomarkers predicting pathological complete response to neoadjuvant chemotherapy in breast cancer[J]. Am J Clin Pathol, 2016,145(6):871-878. DOI: 10.1093/ajcp/aqw045. |
[5] | Fowble BL, Einck JP, Kim DN , et al. Role of postmastectomy radiation after neoadjuvant chemotherapy in stage Ⅱ-Ⅲ breast cancer[J]. Int J Radiat Oncol Biol Phys, 2012,83(2):494-503. DOI: 10.1016/j.ijrobp.2012.01.068. |
[6] | Huang EH, Tucker SL, Strom EA , et al. Postmastectomy radiation improves local-regional control and survival for selected patients with locally advanced breast cancer treated with neoadjuvant chemotherapy and mastectomy[J]. J Clin Oncol, 2004,22(23):4691-4699. DOI: 10.1200/JCO.2004.11.129. |
[7] | Overgaard M, Nielsen HM, Overgaard J . Is the benefit of postmastectomy irradiation limited to patients with four or more positive nodes, as recommended in international consensus reports? A subgroup analysis of the DBCG 82 b&c randomized trials[J]. Radiother Oncol, 2007,82(3):247-253. DOI: 10.1016/j.radonc.2007.02.001. |
[8] | EBCTCG (Early Breast Cancer Trialists' Collaborative Group), McGale P, Taylor C , et al. Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality:meta-analysis of individual patient data for 8 135 women in 22 randomised trials[J]. Lancet, 2014,383(9935):2127-2135. DOI: 10.1016/S0140-6736(14)60488-8. |
[9] | Moo TA, El-Tamer M . ASO author reflections: locoregional recu-rrence rates are low with the selective use of pMRT in patients with T1-2 tumors and one to three positive lymph nodes[J]. Ann Surg Oncol, 2018,25(Suppl 3):691-692. DOI: 10.1245/s10434-018-7010-8. |
[10] | 铁剑, 张丝媛 . 乳腺癌新辅助化疗后腋淋巴结1~3枚转移的患者改良根治术后放射治疗的疗效分析[J]. 中华乳腺病杂志(电子版), 2015,9(3):168-172. DOI: 10.3877/cma.j.issn.1674-0807.2015.03.003. |
[11] | Barbosa C Rocha F, Falcone AB, Buzaid AC , et al. Neoadjuvant therapy for breast cancer treatment: an expert panel recommendation from the Brazilian society of breast surgeons 2018[J]. Breast Cancer Res Treat, 2018,172(2):265-272. DOI: 10.1007/s10549-018-4912-x. |
[12] | Shim SJ, Park W, Huh SJ , et al. The role of postmastectomy radiation therapy after neoadjuvant chemotherapy in clinical stage Ⅱ-Ⅲ breast cancer patients with pN0: a multicenter, retrospective study (KROG 12-05)[J]. Int J Radiat Oncol Biol Phys, 2014,88(1):65-72. DOI: 10.1016/j.ijrobp.2013.09.021. |
[13] | Le Scodan R, Selz J, Stevens D , et al. Radiotherapy for stage Ⅱ and stage Ⅲ breast cancer patients with negative lymph nodes after preoperative chemotherapy and mastectomy[J]. Int J Radiat Oncol Biol Phys, 2012,82(1):e1-e7. DOI: 10.1016/j.ijrobp.2010.12.054. |
[14] | Cao L, Ou D, Shen KW , et al. Outcome of postmastectomy radiotherapy after primary systemic treatment in patients with clinical T1-2N1 breast cancer[J]. Cancer Radiother, 2018,22(1):38-44. DOI: 10.1016/j.canrad.2017.07.051. |
[15] | Krug D, Lederer B, Seither F , et al. Post-mastectomy radiotherapy after neoadjuvant chemotherapy in breast cancer: a pooled retrospective analysis of three prospective randomized trials[J]. Ann Surg Oncol, 2019,26(12):3892-3901. DOI: 10.1245/s10434-019-07635-x. |
[16] | Wang X, Xu L, Yin Z , et al. Locoregional recurrence-associated factors and risk-adapted postmastectomy radiotherapy for breast cancer staged in cT1-2N0-1 after neoadjuvant chemotherapy[J]. Cancer Manag Res, 2018,10:4105-4112. DOI: 10.2147/CMAR.S173628. |
[1] | Qian Xiaotao, Shi Ziyi, Hu Ge, Wu Xiaowei. Efficacy of consolidation chemotherapy after radical radiotherapy and chemotherapy for stage Ⅲ-ⅣA esophageal squamous cell carcinoma: a real-world clinical study [J]. Journal of International Oncology, 2024, 51(6): 326-331. |
[2] | Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun. Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer [J]. Journal of International Oncology, 2024, 51(6): 332-337. |
[3] | Wang Ying, Liu Nan, Guo Bing. Advances of antibody-drug conjugate in the therapy of metastatic breast cancer [J]. Journal of International Oncology, 2024, 51(6): 364-369. |
[4] | Gao Fan, Wang Ping, Du Chao, Chu Yanliu. Research progress on intestinal flora and non-surgical treatment of the colorectal cancer [J]. Journal of International Oncology, 2024, 51(6): 376-381. |
[5] | Fan Zhipeng, Yu Jing, Hu Jing, Liao Zhengkai, Xu Yu, Ouyang Wen, Xie Conghua. Predictive value of changes in inflammatory markers for prognosis in patients with advanced non-small cell lung cancer treated with the first-line immunotherapy plus chemotherapy [J]. Journal of International Oncology, 2024, 51(5): 257-266. |
[6] | Yang Lin, Lu Ning, Wen Hua, Zhang Mingxin, Zhu Lin. Study on the clinical relationship between inflammatory burden index and gastric cancer [J]. Journal of International Oncology, 2024, 51(5): 274-279. |
[7] | Liu Pingping, He Xuefang, Zhang Yi, Yang Xu, Zhang Shanshan, Ji Yifei. Risk factors of postoperative recurrence in patients with primary brain glioma and prediction model construction [J]. Journal of International Oncology, 2024, 51(4): 193-197. |
[8] | Wan Fang, Yang Gang, Li Rui, Wan Qijing. Expression levels and clinical significance of serum miR-497 and miR-383 in patients with esophageal cancer [J]. Journal of International Oncology, 2024, 51(4): 204-209. |
[9] | Yao Yixin, Shen Yulin. Predictive value of serum SOCS3 and TXNIP levels for the prognosis of patients with hepatocellular carcinoma treated with TACE [J]. Journal of International Oncology, 2024, 51(4): 217-222. |
[10] | Sa Qiang, Xu Hangcheng, Wang Jiayu. Advances in immunotherapy for breast cancer [J]. Journal of International Oncology, 2024, 51(4): 227-234. |
[11] | Yang Zhi, Lu Yiqiao, Gu Huayan, Ding Jialing, Guo Guilong. Research progress of tumor microenvironment mediated drug resistance in targeted therapy of breast cancer [J]. Journal of International Oncology, 2024, 51(4): 235-238. |
[12] | Sun Weiwei, Yao Xuemin, Wang Pengjian, Wang Jing, Jia Jinghao. Exploration of prognostic factors and nomogram construction for advanced non-small cell lung cancer treated with immunotherapy based on hematologic indexes [J]. Journal of International Oncology, 2024, 51(3): 143-150. |
[13] | Qian Xiaotao, Shi Ziyi, Hu Ge. A real-world clinical study of immunocheckpoint inhibitor maintenance therapy after radical radiotherapy and chemotherapy in stage Ⅲ-ⅣA esophageal squamous cell carcinoma [J]. Journal of International Oncology, 2024, 51(3): 151-156. |
[14] | Li Shuyue, Ma Chenying, Zhou Juying, Xu Xiaoting, Qin Songbing. Progress of radiotherapy in oligometastatic non-small cell lung cancer [J]. Journal of International Oncology, 2024, 51(3): 170-174. |
[15] | Liu Yulan, Jing Haiyan, Sun Jing, Song Wei, Sha Dan. Advances in predicting efficacy and prognostic markers of immunotherapy for gastric cancer [J]. Journal of International Oncology, 2024, 51(3): 175-180. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||